JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06045585 |
Recruitment Status :
Recruiting
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
Sponsor:
Guangdong Second Provincial General Hospital
Information provided by (Responsible Party):
Qing Zhang, Guangdong Second Provincial General Hospital
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | September 11, 2023 | ||||
First Posted Date ICMJE | September 21, 2023 | ||||
Last Update Posted Date | September 21, 2023 | ||||
Actual Study Start Date ICMJE | August 18, 2023 | ||||
Estimated Primary Completion Date | August 31, 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Objective Response Rate [ Time Frame: Month1、Month2、Month3、Month6、Month9、Month12 ] Metric/method of measurement:IWG-2(2007)《Revised response criteria for malignant lymphoma》
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma | ||||
Official Title ICMJE | Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma | ||||
Brief Summary | Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell lymphoma | ||||
Detailed Description | This is a single-center, single-arm, open-treatment clinical study. In this study, approximately 10-20 adult and elderly patients with CD19-positive relapsed or refractory B-cell lymphoma will be enrolled for JY231 infusion therapy. The safety of JY231 was evaluated by observing adverse events after cell therapy. Evaluate the effectiveness of JY231 treatment compared to the results of the subjects' own previous standard treatment regimens or base data. Blood, bone marrow, and cerebrospinal fluid were collected before and 12 months after the JY231 infusion to detection. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Early Phase 1 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Relapsed or Refractory B-cell Lymphoma | ||||
Intervention ICMJE | Biological: infusion of JY231 injection
Infusion of JY231 Injection by dose of 1-10 x10^6 TU/kg、 1-5 x10^7 TU/kg、 5-10 x10^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion(PI evaluation is required).
|
||||
Study Arms ICMJE | Experimental: infusion of JY231 injection
Infusion of JY231 Injection by dose of 1-10 x10^6 TU/kg、 1-5 x10^7 TU/kg、 5-10 x10^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion(PI evaluation is required).
Intervention: Biological: infusion of JY231 injection
|
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
20 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | December 31, 2025 | ||||
Estimated Primary Completion Date | August 31, 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT06045585 | ||||
Other Study ID Numbers ICMJE | JY-CT-23-002 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Current Responsible Party | Qing Zhang, Guangdong Second Provincial General Hospital | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Guangdong Second Provincial General Hospital | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Guangdong Second Provincial General Hospital | ||||
Verification Date | September 2023 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |